Jefferies analyst David Hoang downgraded Melinta Therapeutics to Hold from Buy and cut his price target for the shares to $5 from $14. The analyst sees “deteriorating” fundamentals with the company’s antibiotics sales ramping “too slowly.” The analyst does not see meaningful way for Melinta to drive an inflection in antibiotics sales absent macro changes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.